Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rutgers, The State University of New Jersey
With
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
OBJECTIVES:
* To determine if patients who are treated with a probiotic-containing diet develop infection with one of the probiotic microorganisms while undergoing allogenic hematopoietic stem cell transplantation for a hematologic malignancy or myelodysplastic syndrome.
OUTLINE: Patients receive oral Lactobacillus rhamosus GG (Culturelle DS) once daily beginning when blood counts have recovered without filgrastim (G-CSF) or sargramostim (GM-CSF) support for 3 consecutive days and continuing for 1 year after transplantation.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Currently undergoing allogeneic stem cell transplantation from a related or unrelated donor for a hematologic malignancy or myelodysplastic syndrome
Hematopoietic engraftment as evidenced by recovery of the absolute neutrophil count \> 1000/μL for \> 3 days without filgrastim (G-CSF) support within 30 days of transplant
PATIENT CHARACTERISTICS:
ECOG performance status 0-2
Serum creatinine ≤ 2.0
AST or ALT ≤ 3 times upper limit of normal (ULN)
Total bilirubin ≤ 2.0 times ULN
No clostridium difficile enterocolitis diagnosed during the transplant hospitalization in the peri-transplant period
Able to take medications by mouth
No evidence of graft-vs-host disease
No history of inflammatory bowel disease or other chronic diarrheal illness
No history of hypersensitivity to milk proteins
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
More than 3 months since prior use of probiotics supplements, excluding yogurt and cheeses with live cultures
No concurrent over-the-counter medications or herbal remedies
Clareo Health | Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
